Genetic Testing Services

Selected news for the healthcare topic - Genetic Testing Services, collected since 10/2017. There are 513 items in the archive. This healthcare topic shares news with NeoGenomics, Zacks Investment Research, COVID-19, Oncology and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/18/2022 Global Cancer-Focused Genetic Testing Services Market Size, Trends, Overview and Forecast 2028 dailygram.com by FW on 4 minutes ago 2 views Global Cancer-Focused Genetic Testing Services market is expected to reach a value of over USD xx billion by 2028 end with a CAGR of xx% for the forecast period 2021-2028. FutureWise Research has released a research report that analyzes Cancer-Focused Genetic Testing Services Market trends in order to forecast market growth. The report progresses with an overview of the business ...
5/13/2022 Zacks Investment Research Lowers Fulgent Genetics (NASDAQ:FLGT) to Hold - Transcript Daily transcriptdaily.com Zacks Investment Research cut shares of Fulgent Genetics ( NASDAQ:FLGT – Get Rating ) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves ...
5/12/2022 Zacks Investment Research Lowers Fulgent Genetics (NASDAQ:FLGT) to Hold baseballnewssource.com Zacks Investment Research downgraded shares of Fulgent Genetics ( NASDAQ:FLGT – Get Rating ) from a buy rating to a hold rating in a research note released on Monday morning, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process ...
5/10/2022 Fulgent Genetics (NASDAQ:FLGT) Downgraded to “Hold” at Zacks Investment Research - The Cerbat Gem thecerbatgem.com Fulgent Genetics ( NASDAQ:FLGT – Get Rating ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process ...
4/30/2022 Fulgent Genetics (NASDAQ:FLGT) Upgraded by Zacks Investment Research to “Buy” - Mayfield Recorder Mayfield Recorder ... buy rating in a research report released on Tuesday, Zacks.com reports. Zacks Investment Research currently has $65.00 price target on the stock.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/30/2022 Fulgent Genetics (NASDAQ:FLGT) Upgraded by Zacks Investment Research to “Buy” modernreaders.com ... rating in a research note issued to investors on Tuesday morning, Zacks.com reports. They currently have $65.00 target price on the stock.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/29/2022 Fulgent Genetics (NASDAQ:FLGT) Lifted to “Buy” at Zacks Investment Research - The Cerbat Gem thecerbatgem.com ... to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $65.00 price objective on the stock.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/28/2022 Fulgent Genetics (NASDAQ:FLGT) Raised to Buy at Zacks Investment Research zolmax.com ... on the stock. Zacks Investment Research ‘s price target points to a potential upside of 17.97% from the company’s previous close.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/27/2022 Fulgent Genetics (NASDAQ:FLGT) Upgraded to Buy by Zacks Investment Research Ticker Report ... in a research report sent to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has $65.00 price objective on the stock.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/27/2022 Fulgent Genetics (NASDAQ:FLGT) Upgraded by Zacks Investment Research to Buy etfdailynews.com ... price on the stock. Zacks Investment Research ‘s target price indicates a potential upside of 18.20% from the company’s current price.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/27/2022 Fulgent Genetics (NASDAQ:FLGT) Lifted to “Buy” at Zacks Investment Research defenseworld.net ... target on the stock. Zacks Investment Research ‘s price objective indicates a potential upside of 18.20% from the stock’s current price.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/25/2022 NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay neogenomics.com FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost.The Lilly Lung Cancer Sponsored Testing Program will utilize the NeoTYPE® DNA and ...
4/25/2022 2022-04-25 | NDAQ:NEO | Press Release | NeoGenomics Inc. stockhouse.com NEO 1 hour ago FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost.The Lilly Lung Cancer Sponsored Testing Program will utilize the ...
4/22/2022 Fulgent Genetics (NASDAQ:FLGT) Cut to “Sell” at Zacks Investment Research baseballnewssource.com ... Get Rating ) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/22/2022 Fulgent Genetics (NASDAQ:FLGT) Cut to “Sell” at Zacks Investment Research - Ticker Report Ticker Report ... FLGT – Get Rating ) from a hold rating to a sell rating in a research report report published on Tuesday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/20/2022 Zacks Investment Research Lowers Fulgent Genetics (NASDAQ:FLGT) to Sell slatersentinel.com ... Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/20/2022 Zacks Investment Research Lowers Fulgent Genetics (NASDAQ:FLGT) to Sell - Mayfield Recorder Mayfield Recorder ... Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/20/2022 Fulgent Genetics (NASDAQ:FLGT) Downgraded by Zacks Investment Research to “Sell” etfdailynews.com Zacks Investment Research downgraded shares of Fulgent Genetics ( NASDAQ:FLGT – Get Rating ) from a hold rating to a sell rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and ...
4/20/2022 Zacks Investment Research Lowers Fulgent Genetics (NASDAQ:FLGT) to Sell modernreaders.com ... Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Zacks.com reports.According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...
4/20/2022 Fulgent Genetics (NASDAQ:FLGT) Downgraded by Zacks Investment Research defenseworld.net ... Äì Get Rating ) from a hold rating to a sell rating in a research report report published on Tuesday morning, Zacks.com reports.According to Zacks, ‚ÄúFulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company‚Äôs technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to ...